ReviewMedicina (Kaunas, Lithuania)2022
Acute Kidney Injury: Biomarker-Guided Diagnosis and Management.
Review in Medicina (Kaunas, Lithuania), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 69 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
69 citing papers in PubMed, 1 synthesis or guideline pooled it, 129 citations in OpenAlex.
- The efficacy of novel biomarkers for the early detection and management of acute kidney injury: A systematic review.PloS one · 2025Pooled it
- Impact of Using Biomarkers in Eligibility Criteria in Acute Kidney Injury Randomized Controlled Trials: A Systematic Review and Methodological Meta-Analysis.Kidney medicine · 2026Article
- Biomarkers in Clinical Medicine Research: A Literature Survey in the PubMed Database and a Critical Evaluation.Journal of clinical medicine · 2026Review
- CMKLR1 as a Therapeutic Target: Vitamin D-Mediated Suppression of Inflammation and Oxidative Stress in SA-AKI.Molecular biotechnology · 2026Article
- Deubiquitinase USP35 regulates MDM4 degradation to promote endothelial ferroptosis and renal injury progression.Cell death discovery · 2026Article
- Natural compounds targeting inflammatory signaling and cell adhesion molecules in ischemic acute kidney injury.Archives of pharmacal research · 2026Review
- Biomarker-Based Diagnosis and Risk Stratification in Sepsis-Associated Acute Kidney Injury: From Molecular Mechanisms to Multimarker Panels.Diagnostics (Basel, Switzerland) · 2026Review
- Prediction of acute kidney injury in patients with acute pesticide poisoning using the PKIP score.Scientific reports · 2026Article
- The value of NLRP, PCT, and HBP for sepsis-associated acute kidney injury and the effect of anti-inflammatory drugs.Medicine · 2026Article
- The global epidemiology of acute kidney injury: challenges and opportunities.Nature reviews. Nephrology · 2026Review
- The role of multimodal ultrasound in assessing renal microcirculatory perfusion in cases of acute kidney injury.BMC nephrology · 2026Article
- The Role of Biomarkers in Personalized Anesthesia: From Physiological Parameters to Molecular Diagnostics.Biomedicines · 2026Review
- Neutrophil extracellular traps and acute kidney injury: a narrative review.Frontiers in immunology · 2026Review
- From empirical practice to precision medicine: developing a methodology for adjusting traditional Chinese medicine formula dosages based on eight multicenter clinical studies.Frontiers in pharmacology · 2026Article
- Diagnostic Biomarkers and Targeted Drug Prediction for Acute Kidney Injury: A Computational ApproachEndocrine, metabolic & immune disorders drug targets · 2026Article
- Keratin 20 Suppresses Exosomal Secretion of Peroxiredoxin 2 and Ferroptosis in Acute Kidney Injury.Journal of the American Society of Nephrology : JASN · 2026Article
- Construction of a Machine Learning-Based Risk Prediction Model for Drug-Induced Acute Kidney Injury in Elderly Patients.International journal of nephrology and renovascular disease · 2026Article
- Triglyceride-glucose index and triglyceride-to-high-density lipoprotein cholesterol ratio as novel predictors of acute kidney injury: an analysis of the UK biobank.Renal failure · 2025Article
- Clinical Profiles and Mortality-Associated Risk Factors in Patients with Acute Kidney Injury from Atlixco, Puebla, Mexico.Diagnostics (Basel, Switzerland) · 2025Article
- Kim-1-targeted multimodal nanoprobes for early diagnosis and monitoring of sepsis-induced acute kidney injury.Apoptosis : an international journal on programmed cell death · 2025Article
9 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute kidney injury (AKI) is a common clinical syndrome that is characterized by abnormal renal function and structure. The Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference in 2019 reviewed the stages of AKI and the definitions of AKI-related terminologies, and discussed the advances in the last decade. Along with serum creatinine level and urine output, more accurate novel biomarkers for predicting AKI are being applied for the early detection of renal dysfunction. A literature search was conducted in PubMed, Scopus, Medline, and ClinicalTrials.gov using the terms AKI and biomarker, combined with diagnosis, management, or prognosis. Because of the large volume of data (160 articles) published between 2005 and 2022, representative literature was chosen. A number of studies have demonstrated that new biomarkers are more sensitive in detecting AKI in certain populations than serum creatinine and urine output according to the recommendations from the Acute Disease Quality Initiative Consensus Conference. To be specific, there is a persistently unresolved need for earlier detection of patients with AKI before AKI progresses to a need for renal replacement therapy. Biomarker-guided management may help to identify a high-risk group of patients in progression to severe AKI, and decide the initiation time to renal replacement therapy and optimal follow-up period. However, limitations such as biased data to certain studied populations and absence of cutoff values need to be solved for worldwide clinical use of biomarkers in the future. Here, we provide a comprehensive review of biomarker-based AKI diagnosis and management and highlight recent developments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.